Periodic disclosure for the financial products referred to in Article 8, paragraphs 1, 2 and 2a, of Regulation (EU) 2019/2088 and Article 6, first paragraph, of Regulation (EU) 2020/852

Published on: 30 June 2026

Sustainable investment means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy is** a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not.

Product name:

- MED VET S.L.P.

Legal entity identifier:

- 9695009YB509RFXA8G16

Environmental and/or social characteristics

Did this financial product have a sustainable investment objective?

☐ **Yes**	☒ **No**
☐ It made **sustainable investments with an environmental objective:** ___%	☐ It **promoted Environmental/Social (E/S) characteristics** and while it did not have as its objective a sustainable investment, it had a proportion of ___ % of sustainable investments
☐ in economic activities that qualify as environmentally sustainable under the EU Taxonomy	☐ with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy
☐ in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy	☐ with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
	☐ with a social objective
☐ It made **sustainable investments with a social objective:** ___%	☒ It promoted E/S characteristics, but **did not make any sustainable investments**

To what extent were the environmental and/or social characteristics promoted by this financial product met?

MED Vet S.L.P. (or 'the Fund') and its management approach is focused on the contribution of social and environmental factors. MED Vet S.L.P. has defined Environmental and Social (E/S) characteristics that companies should promote:

1) The Fund has a focus on healthcare companies promoting **eco-conception and sustainable use of natural resources and contributing to carbon neutrality**. We therefore have sought to promote the following environmental characteristics:

- Mitigation of adverse impact on the environment,
- Companies' carbon footprint and exposure to climate-related risks,
- Use of renewable energy,
- Formalized environmental policy,
- Hazardous and non-hazardous waste management.

2) MED Vet S.L.P. investment strategy also seeks to invest in healthcare companies with initiatives implemented regarding **employees' and stakeholders' work conditions and promoting business ethics**. We therefore promote the following social characteristics:

- Employees' wellbeing, safety, satisfaction, and retention,
- Business ethics,
- Gender equality.

Sustainability indicators measure how the environmental or social characteristics promoted by the financial product are attained.

How did the sustainability indicators perform?

Ceva Sante Animale SA have completed their 2025 ESG reporting. For details on 2025 performance, please refer to Appendix I.

…and compared to previous periods?

As above.

What were the objectives of the sustainable investments that the financial product partially made and how did the sustainable investment contribute to such objectives?

Not applicable. The financial product does not have a sustainable investment objective.

Principal adverse impacts are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.

How did the sustainable investments that the financial product partially made not cause significant harm to any environmental or social sustainable investment objective?

Not applicable (please see above).

How were the indicators for adverse impacts on sustainability factors taken into account?

Not applicable (please see above).

Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:

Not applicable (please see above).

The EU Taxonomy sets out a "do not significant harm" principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.

The "do no significant harm" principle applies only to those investments underlying the financial product that take into account the Union criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the Union criteria for environmentally sustainable economic activities.

Any other sustainable investments must also not significantly harm any environmental or social objectives.

How did this financial product consider principal adverse impacts on sustainability factors?

PAIs are considered throughout the entire investment cycle, from the initial negative and positive screening phases through due diligence.

During the due diligence phase, an assessment is conducted to verify the company's readiness to report on PAI metrics. This assessment helps identify existing gaps which can then be addressed in the early stages of onboarding and/or during ARCHIMED annual ESG reporting campaign and hold period.

Our ESG reporting process monitors this by asking investee companies for PAI-related data on an annual basis. Any material impacts are discussed during the annual follow-up reviews, which takes place at the end of the campaign. Please refer to Appendix I for more information.

What were the top investments of this financial product?

The list includes the investments constituting **the greatest proportion of investments** of the financial product during the reference period which is:

01/01/25 – 31/12/25

Largest investments	Sector	% Assets	Country
Ceva Sante Animale SA	Animal & Environmental Health	100	France

What was the proportion of sustainability-related investments?

MED Vet S.L.P currently holds investments in Ceva Sante Animale SA within the Animal & Environmental Health industry and are actively promoting E/S characteristics.

Asset allocation describes the share of investments in specific assets.

- ***What was the asset allocation?***



#1 Aligned with E/S characteristics includes the investments of the financial product used to attain the environmental or social characteristics promoted by the financial product.
#2 Other includes the remaining investments of the financial product which are neither aligned with the environmental or social characteristics, nor are qualified as sustainable investments
The category **#1A Aligned with E/S characteristics** covers :
- The sub-category **#1A Sustainable** covers sustainable investments with environmental or social objectives.
- The sub-category **#1B Other E/S characteristics** covers investments aligned with the environmental or social characteristics that do not qualify as sustainable investments.

As at 31/12/25, 100% of the Fund's invested amount were allocated to investments that promotes E/S characteristics.

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

Enabling activities directly enable other activities to make a substantial contribution to an environmental objective.

Transitional activities are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.

- ***In which economic sectors were the investments made?***

All investments made through MED Vet S.L.P lifetime were made in Animal and Environmental Health sector.

To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?

Not Applicable. MED Vet S.L.P SLP does not conduct sustainable investments with an environmental objective aligned with the EU taxonomy. Instead, the Fund's focus is on the promotion of environmental and social characteristics

Taxonomy-aligned activities are expressed as a share of:
- **turnover** reflecting the share of revenue from green activities of investee companies
- **capital expenditure** (CapEx) showing the green investments made by investee companies, e.g. for a transition to a green economy.
- **operational expenditure** (OpEx) reflecting green operational activities of investee companies.

Did the financial product invest in fossil gas and/or nuclear energy related activities that comply with EU Taxonomy[1]?

☐ Yes :

☐ In fossil gas ☐ In nuclear energy

☒ No

The graphs below show in green the percentage of investments that were aligned with the EU Taxonomy. As there is no appropriate methodology to determine the taxonomy-alignment of sovereign bonds*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investment of the financial product other than sovereign bonds.





This graph represents 100% of the total investment.

****For the purpose of these graphs, “sovereign bonds” consist of all sovereign exposure.***

[1] Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change (“climate change mitigation”) and do not significantly harm any EU Taxonomy objective – see explanatory note in the left hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.

What was the share of investments made in transitional and enabling activities?

Not applicable. The Fund does not invest or plan to invest in transitional nor enabling activities in the sense of the EU Taxonomy.

How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?

Not applicable. As stated above, MED Vet S.L.P investments do not follow an environmentally sustainable investment objective in the sense of the EU Taxonomy. Instead, they focus on the promotion of social and environmental characteristics.

are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under Regulation (EU) 2020/852.

What was the share of sustainable investments with an environmental objective not aligned with the EU Taxonomy ?

MED Vet S.L.P investments do not pursue an environmental objective as laid out in the EU Taxonomy. Hence, 0% of the Fund's investments are aligned with the EU Taxonomy.

What was the share of socially sustainable investments ?

Not applicable, as the Fund's investments contributed to E/S characteristics and do not commit to investing in socially sustainable investments.

What investments were included under "other", what was their purpose and were there any minimum environmental or social safeguards ?

None of MED Vet S.L.P's investment fall into this category.

What actions have been taken to meet the environmental and/or social characteristics during the reference period?

During the reference period, ESG data were collected for all investee companies, comprising metrics based on SASB and other applicable standards. At the end of the reference period, follow-up reviews were conducted including overall progress, gap analysis and establishment of priorities for 2026.

Specific actions implemented at investee company level are specified in the Fund's Sustainability Report, and regularly to our investors in quarterly reports of the Fund.

How did this financial product perform compared to the reference benchmark?

Not applicable. The Fund does not use a benchmark.

Reference benchmarks are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.

- ***How does the reference benchmark differ from a broad market index?***

  Not applicable.

- ***How did this financial product perform with regard to the sustainability indicators to determine the alignment of the reference benchmark with the environmental or social characteristics promoted?***

  Not applicable.

- ***How did this financial product perform compared with the reference benchmark?***

  Not applicable.

- ***How did this financial product perform compared with the broad market index?***

  Not applicable.

APPENDIX I: ARCHIMED MED Vet S.L.P Principal Adverse Impact Indicators 2025/2024

<table>
<tr><th colspan="2">Adverse sustainability indicator</th><th>Metric</th><th>Unit</th><th>2025</th><th>2024</th><th>Explanation[12]</th><th>Actions Taken[13]</th></tr>
<tr><td colspan="8">CLIMATE AND OTHER ENVIRONMENT-RELATED INDICATORS</td></tr>
<tr><td rowspan="7">GHG (Greenhouse Gas) Emissions</td><td rowspan="4">1. GHG emissions (GP share)</td><td>Scope 1 GHG emissions and</td><td>tonnes</td><td>1,001</td><td>N/A</td><td rowspan="6">In 2025, Ceva completed a full Scope 1, 2, and 3 GHG inventory based on 2024 data, supporting an accurate disclosure using company specific data rather than sectoral estimates. As comprehensive carbon emissions data are not available for the reference period, prior year emissions data (2024) are scaled using a revenue-based extrapolation.</td><td rowspan="6">Ceva performs an annual carbon footprint covering Scopes 1, 2 and 3 under the GHG Protocol, spanning 100% of its sites. Ceva have a dedicated climate working group to collect data and embed the group’s climate strategy across all sites.</td></tr>
<tr><td>Scope 2 GHG emissions</td><td>tonnes</td><td>901</td><td>N/A</td></tr>
<tr><td>Scope 3 GHG emissions</td><td>tonnes</td><td>6,855</td><td>N/A</td></tr>
<tr><td>Total GHG emissions</td><td>tonnes</td><td>8,756</td><td>N/A</td></tr>
<tr><td>2. Carbon footprint</td><td>Carbon footprint</td><td>tonnes/ €M</td><td>25</td><td>N/A</td></tr>
<tr><td>3. GHG intensity of investee companies</td><td>GHG intensity of investee companies</td><td>tonnes/ €M</td><td>148</td><td>N/A</td></tr>
<tr><td>4. Exposure to companies active in the fossil fuel sector</td><td>Share of investments in companies active in the fossil fuel sector</td><td>%</td><td>Nil</td><td>N/A</td><td>ARCHIMED invests exclusively in companies across the healthcare industries and thus has no exposure to the fossil fuel sector.</td><td>Not applicable.</td></tr>
<tr><td></td><td>5. Share of non-renewable energy consumption and production</td><td>Share of non-renewable energy consumption and non-renewable energy production of investee companies from non-renewable energy sources compared to renewable energy sources, expressed as a percentage</td><td>%</td><td>99</td><td>N/A</td><td rowspan="2">Ceva's energy is predominantly from non-renewable sources such as grid electricity and natural gas for heat and steam. Through its decarbonization plan, Ceva has identified key energy efficient and reduction measures to reduce reliance on non-renewable energy in coming years.</td><td rowspan="2">To improve renewable energy consumption, Ceva has installed its first on-site solar panel with further investments being assessed to enhance renewable energy production. The group has also commenced work to acquire guarantees of origin, so part of its purchased electricity is renewable. The group continues to run site specific energy-efficiency programmes under its ESG roadmap noting that increasing renewable energy consumption is a key action within the group’s 2030 decarbonization plan.</td></tr>
<tr><td></td><td>6. Energy consumption intensity per high impact climate sector</td><td>Energy consumption in GWh per million EUR of revenue of investee companies, per high impact climate sector</td><td>GWh/ €M</td><td>0.01</td><td>N/A</td></tr>
</table>

[12] The Fund has strictly followed the definitions of Annex I of the Final Report on draft Regulatory Technical Standards, dated 4 December 2023, for compiling the various PAI indicators.

[13] For a more detailed overview of ARCHIMED’s Responsible Investment strategy at a fund level please refer to MED Platform II SFDR Periodic Disclosure for 2025.

Biodiversity	7. Activities negatively affecting biodiversity-sensitive areas	Share of investments in investee companies with sites/operations located in or near to biodiversity-sensitive areas where activities of those investee companies negatively affect those areas	%	Nil	N/A	Ceva do not have any sites/operations located in or near biodiversity-sensitive areas where they could negatively affect those areas.	All laboratory and clinical research activities are conducted within established indoor facilities in industrial or commercial zones, with no direct or known negative impact on surrounding ecosystems or biodiversity.
Water	8. Emissions to water	Tonnes of emissions to water generated by investee companies per million EUR invested, expressed as a weighted average	tonnes/ €M	Nil	N/A	Ceva reported zero emissions to water in 2025.	Not applicable
Waste	9. Hazardous waste ratio	Tonnes of hazardous waste generated by investee companies per million EUR invested, expressed as a weighted average	tonnes/ €M	0.01	N/A	Ceva generates very low quantities of hazardous waste and all waste is segregated and managed under the environmental, health and safety (EHS) roadmap and the ISO 14001-aligned environmental management system, with controlled storage and handling of hazardous substances. However, it is worth noting that as the company evolves and mature in ESG data collection, the processes of tracking and reporting waste data will improve. This means that reported data may not yet capture the full picture, and values are expected to become more precise and comprehensive in future reporting periods as data maturity improves.	Ceva has a reduction and recycling programme which supports the Group's circular-economy commitment. During the reference period, 24% of waste was recycled and total waste fell by more than 30% due to improve data collection and monitoring across sites. ARCHIMED's S&I team will continue to actively support Ceva to establish robust environmental data tracking and reporting systems, ensuring that energy, waste, water and other key KPIs are accurately identified, categorized and measured in line with applicable regulatory definitions.
ARCHIMED Additional environmental indicator	4. Investments in companies without carbon emission reduction initiatives	Share of investments in investee companies without carbon emission reduction initiatives aimed at aligning with the Paris Agreement	%	Nil	N/A	Ceva has active and ongoing carbon-reduction initiatives and a formal decarbonization aligned with the Paris Agreement	Ceva have a dedicated climate strategy and across all sites with board oversight. A target to cut Scope 1 & 2 emissions by 30% by 2030 which is on track including key actions such as on-site solar panels, guarantees of origin for renewable electricity, biomass and site energy-efficiency projects. The group continues to work on Scope 3 value-chain mapping to ensure emission reduction targets are both feasible and in line with SBTi 1.5°C pathway.

Adverse sustainability indicator		Metric	Unit	2025	2024	Explanation[14]	Actions Taken[15]
SOCIAL AND EMPLOYEE, RESPECT FOR HUMAN RIGHTS, ANTI-CORRUPTION AND ANTI-BRIBERY MATTERS							
Social and Employee Matters	10. Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises	Share of investments in investee companies that have been involved in violations of the UNGC principles or OECD Guidelines for Multinational Enterprises	%	Nil	N/A	No violations took place in 2025.	As part of ARCHIMED's Sustainability Essentials framework, investee companies are encouraged to develop and maintain policies on the following non-exhaustive, social and governance topics: (a) Code of Conduct, Anti-Bribery and Corruption, Grievance and Whistleblowing Mechanism (b) Employee Wellbeing & Engagement Approach (c) Responsible Supply Chain (d) Health and Safety (e) Cybersecurity and Data Privacy and Protection Potential ESG incidents and controversies are also assessed through multiple channels such as the annual ESG Reporting Campaign and through ongoing engagement with deal team members. ESG topics are also discussed at board level at least twice per year, with ARCHIMED holding multiple board seats across its portfolio. In addition to the Sustainability Essentials, ARCHIMED Value Creation Teams (VCTs) support investee companies in strengthening these frameworks, ensuring high standards of corporate governance, accountability, and transparency.
	11. Lack of processes and compliance mechanisms to monitor compliance with UN Global Compact principles and OECD Guidelines for Multinational Enterprises	Share of investments in investee companies without policies to monitor compliance with the UNGC principles or OECD Guidelines for Multinational Enterprises or grievance /complaints handling mechanisms to address violations of the UNGC principles or OECD Guidelines for Multinational Enterprises	%	Nil	N/A	Ceva maintains a comprehensive Business Code of Conduct that establishes explicit behavioural expectations across human rights, labour practices, environmental standards, and ethical business conduct. This will continue to be monitored as part of the annual ESG reporting cycle and through ARCHIMED's Sustainability Essentials which requires investee companies to have policies in line with OECD and UNGC principles.	

[14] The Fund has strictly followed the definitions of Annex I of the Final Report on draft Regulatory Technical Standards, dated 4 December 2023, for compiling the various PAI indicators.

[15] For a more detailed overview of ARCHIMED's Responsible Investment strategy at a fund level please refer to MED Platform II SFDR Periodic Disclosure for 2025.

	12. Unadjusted gender pay gap	Average unadjusted gender pay gap of investee companies	%	15	N/A	Ceva has a positive unadjusted pay gap in line with market benchmarks demonstrating the Group's commitment to ensuring fair and equitable pay compensation for all employees. Noting, the unadjusted gender pay gap does not account for differences in role, seniority, or function, and as such does not necessarily reflect unequal pay for equivalent work.	Ceva has a strong female representation through the organisation with women making up more than 40% of the total and upper management. The Group's gender-equality programme and management-pipeline development are the principal levers expected to raise board and senior management diversity over the coming years.
	13. Board gender diversity	Average ratio of female to male board members in investee companies	%	7	N/A		
	14. Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons)	Share of investments in investee companies involved in the manufacture or selling of controversial weapons	%	Nil	N/A	ARCHIMED invests exclusively in companies across the healthcare industries and thus has no exposure to controversial weapons.	Not applicable.
ARCHIMED Additional social indicator	1. Investments in companies without workplace accident prevention policies	Share of investments in investee companies without a workplace accident prevention policy	%	Nil	N/A	Ceva has a formal health and safety policy that covers commitment to a safe working environment, hazard identification, control measures, employee training, incident-reporting guidelines, regular monitoring and legal compliance.	The health and safety policy is operationalised through its EHS roadmap with facility safety visits, statistical analysis of accident causes, an enhanced focus on identifying and reporting dangerous situations, near-misses monitored and ongoing reporting to senior stakeholders on a regular basis.